secwatch.observer — SEC 8-K summary
======================================

Issuer:     Akari Therapeutics Plc (AKTX)
CIK:        0001541157
Form:       8-K
Filed at:   2026-03-02T23:59:59+00:00
Accession:  0001493152-26-008570
Event type: other
Sentiment:  neutral
Materiality: 0.15
Item codes: 5.07
LLM model:  deepseek-v4-flash:cloud@v2

Akari shareholders approve warrant exercises and share issuances at special meeting
--------------------------------------------------------------------------------

- Shareholders voted overwhelmingly to approve exercisability of Series G, Placement Agent, Pre-Funded, and Note Exchange warrants.
- Proposals covered up to ~10M ADSs from Series G/Placement Agent warrants and ~19M ADSs from Pre-Funded/Note Exchange warrants.
- All five resolutions passed with over 99% of votes cast in favor; abstentions negligible.
- Meeting held March 2, 2026; matters related to capital raises and note exchanges from Dec 2025 and Jan 2026.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1541157/000149315226008570/0001493152-26-008570-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1541157/000149315226008570/form8-k.htm
  HTML page:      https://secwatch.observer/filing/0001493152-26-008570

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer